Home > Drug List > Neratinib > Indications of Neratinib

Indications of Neratinib

Extended Adjuvant Treatment for Early Breast Cancer

Neratinib is indicated as a monotherapy for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant therapy based on trastuzumab.

Advanced or Metastatic Breast Cancer

Neratinib in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based treatment regimens in the metastatic setting.

FDA，2021.06